Antigen News and Research

RSS

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

When the American Society of Hematology convenes its 53rd Annual Meeting and Exposition on Dec. 10-13 in San Diego, Calif., researchers from Moffitt Cancer Center will break a new record for Moffitt participants with one plenary presentation, 16 oral presentations and more than 50 poster presentations on new research results in a variety of meeting programs that focus on blood cancer basic science and clinical applications, including bone marrow transplantation and clinical trials results.

5 Dec 2011

New rapid blood test for early diagnosis of cryptococcosis

Research conducted at University of Nevada, Reno and licensed through the University's Technology Transfer Office is featured in the technology transfer publication "Better World Report" for a remarkable second year in a row.

3 Dec 2011

Mutation on surface of human red blood cells provides protection against vivax malaria

A mutation on the surface of human red blood cells provides protection against malaria caused by the parasite Plasmodium vivax, research led by Case Western Reserve University School of Medicine shows.

2 Dec 2011

Potential test to diagnose membranous nephropathy in early stages

Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) has led to the development of a test that can help diagnose membranous nephropathy in its early stages.

1 Dec 2011

Counterparts of memory cells ward off microbial foes

The immune system possesses a type of cell that can be activated by tissues within the body to remind the immune system not to attack our own molecules, cells and organs, UCSF researchers have discovered.

29 Nov 2011

Blood stem cells engineered to create cancer-killing T-cells

Researchers from UCLA's cancer and stem cell centers have demonstrated for the first time that blood stem cells can be engineered to create cancer-killing T-cells that seek out and attack a human melanoma. The researchers believe this approach could be useful in 40 percent of Caucasians with this malignancy.

29 Nov 2011

Abbott, GSK expand collaboration to develop additional companion diagnostic test

Abbott announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program.

29 Nov 2011

New swine flu virus alarms health officials

According to the Centers for Disease Control and Prevention (CDC), three cases of a new flu virus have been confirmed. These originated in pigs but apparently spread from person to person, in three Iowa children.

28 Nov 2011

Leica Microsystems announces availability of ChromoPlex 1 Dual Detection for BOND

Leica Microsystems announced today the availability of Leica ChromoPlex 1 Dual Detection for BOND, the first fully automated one-step detection system allowing the co-visualization of mouse and rabbit antibodies on a single slide.

28 Nov 2011

Randox expand range of immunoturbidimetric proteins

With the recent launch of the Haptoglobin and Ceruloplasmin assays Randox now have one of the largest ranges of immunoturbidimetric proteins on the market. All reagents are liquid ready to use for added convenience; furthermore, automated applications are available for most chemistry systems eliminating the need for specialised protein analysers.

From Randox Laboratories Ltd. 24 Nov 2011

Men less willing to participate in cancer screening than women

Although men have higher cancer mortality rates than women, they are less willing to be screened for cancer, according to a study conducted by researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Sanoa Consulting LLC, Muscle Shoals, Ala., and the New York University College of Dentistry.

23 Nov 2011

Scientists design math model that could guide future prostate cancer treatments

Scientists have designed a first draft of a mathematical model that someday could guide treatment decisions for advanced prostate cancer, in part by helping doctors predict how individual patients will respond to therapy based on the biology of their tumors.

22 Nov 2011

Abbott receives FDA approval for new Chagas assay

The U.S. Food and Drug Administration today approved the first test for use as an additional, more specific test on human serum or plasma specimens found to be positive for antibodies to Trypanosoma cruzi.

19 Nov 2011

Inovio announces results from SynCon avian influenza vaccine Phase I study

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.

18 Nov 2011

Advaxis licenses ISG15 tumor antigen from University of Pennsylvania

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania.

16 Nov 2011

Midatech receives Swissmedic approval to start trial of insulin-coated gold nanoparticle

Midatech Ltd., a global leader in the design, development, synthesis and manufacture of nanomedicines, announced today it has received Swissmedic approval to start the First-in-Human clinical trial with insulin-coated gold nanoparticles, which will be coordinated through its Swiss subsidiary PharMida AG.

15 Nov 2011

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.

15 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

New breast and ovarian cancer vaccine in the pipeline: Study

A new vaccine is being tried clinically to combat tumor cells in a small study of advanced breast and ovarian cancer patients. The results show that there is improvement in overall survival times and stopping the disease for a handful of breast cancer patients.

8 Nov 2011

Viewpoints: Weighing the ballot measures in Miss. and Ohio; the super committee's task

For all their sincerity and fervor, proponents of the personhood movement represent a small minority nationwide. In Gallup polls, support for a total abortion ban is almost exactly where it was in 1973 -;at just over 20%, despite a rise in backing for limitations. Most people certainly don't want homicide charges brought against women who choose to have abortions or doctors who perform them.

8 Nov 2011